Correction to Results, Table, and Figure in: Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.

The authors have reported to CHEST that an error appeared in the text, Figure 3, and Tables 3 and 4 in “Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD” (Chest. 2017;151(2):340-357).

In line 4 of the Results/Efficacy section, the $P$ value should read $P < .0001$ in PINNACLE-1 and $P < .02$ in PINNACLE-2. In addition, the legends for Figures 3 and 4 should read mean change ($\pm$ SE). A corrected version of Figure 3 is available online.

In Table 3, the third LSM entry in column 1 reading across to PINNACLE-2 (GP MDI), value should read $-.036d$.

In Table 4, the number of patients with TEAEs related to study treatment in the Placebo MDI group in PINNACLE-2 should be 15 (6.7).

These corrections do not change the conclusions. The online article has been corrected.